A Phase I trial of TILT-123 in combination with tumor infiltrating lymphocyte (TIL) for metastatic melanoma.
Phase of Trial: Phase I
Latest Information Update: 21 Dec 2016
At a glance
- Drugs TILT 123 (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 21 Dec 2016 New trial record
- 14 Dec 2016 According to a TILT Biotherapeutics media release, company plans to start first phase I clinical trials in early 2018.